Meet The Professors VOL 4, ISSUE 1

Select publications

Birnbaum D et al. Basal and luminal breast cancers: Basic or luminous? Int J Oncol 2004;25(2):249-58. Abstract

Brenton JD et al. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005;23(29):7350-60. Abstract

Burstein HJ et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study. San Antonio Breast Cancer Symposium 2005;Abstract 4.

Carey LA et al. The triple negative paradox: Primary tumor chemosensitivity of the basal-like breast cancer (BBC) phenotype. San Antonio Breast Cancer Symposium 2004;Abstract 1023.

Chlebowski RT et al. Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005;97(6):439-48. Abstract

D’Adamo DR et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23(28):7135-42. Abstract

Hainsworth JD et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23(31):7889-96. Abstract

Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23(11):2544-55. Abstract

Hurwitz HI et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23(15):3502-8. Abstract

Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract

Johnson DH et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91. Abstract

Kabbinavar FF et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005a;23(16):3697-705. Abstract

Kabbinavar FF et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005b;23(16):3706-12. Abstract

Kindler HL et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23(31):8033-40. Abstract

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005a;23(4):792-9. Abstract

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005b;Abstract 3.